KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Invested Capital (2018 - 2025)

Castle Biosciences' Invested Capital history spans 7 years, with the latest figure at $480.9 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 3.24% year-over-year to $480.9 million; the TTM value through Dec 2025 reached $480.9 million, up 3.24%, while the annual FY2025 figure was $480.9 million, 3.24% up from the prior year.
  • Invested Capital for Q4 2025 was $480.9 million at Castle Biosciences, up from $477.1 million in the prior quarter.
  • Across five years, Invested Capital topped out at $480.9 million in Q4 2025 and bottomed at $378.8 million in Q2 2023.
  • The 5-year median for Invested Capital is $417.1 million (2021), against an average of $423.9 million.
  • The largest annual shift saw Invested Capital surged 269.53% in 2021 before it decreased 10.17% in 2023.
  • A 5-year view of Invested Capital shows it stood at $411.7 million in 2021, then fell by 3.06% to $399.2 million in 2022, then dropped by 1.97% to $391.3 million in 2023, then rose by 19.06% to $465.9 million in 2024, then grew by 3.24% to $480.9 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Invested Capital are $480.9 million (Q4 2025), $477.1 million (Q3 2025), and $465.4 million (Q2 2025).